866-997-4948(US-Canada Toll Free)

Global Personalized Medicine Partnering 2010-2015: Deal trends, players, financials and forecasts

Published By :

Current Partnering

Published Date : Jun 2015

Category :

Biotechnology

No. of Pages : 469 Pages

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1000 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of personalized medicine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. The chapter also includes deal trends by big pharma and most active of all biopharma.

Chapter 3 covers the average financial deal terms for deals signed in the personalized medicine field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.

Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in personalized medicine partnering and dealmaking since 2010.

Chapter 4 provides a review of the leading biomarker deals since 2010 by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a review of the leading companion diagnostics deals since 2010 by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 6 provides a review of the leading pharmacogenomics deals since 2010 by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 7 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of personalized medicine deals including biomarker, companion diagnostic, pharmacogenomics, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 10 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 11 provides a comprehensive and detailed review of personalized medicine partnering deals signed and announced since January 2010. The chapter is organized by specific personalized medicine, biomarkers, companion diagnostics and pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 12 brings the report to a conclusion by looking ahead to the future of personalized medicine partnering. Newly introduced to provide readers with potential prospects and partnering insights this chapter selects emerging companies to watch in 2015 and details their recent deal making and financial activities. These companies could be potential targets for those who want to invest or partner in the coming months.

In addition, a comprehensive appendix is provided organized by personalized medicine partnering company A-Z , deal type, and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 
.

Report scope

Personalized Medicine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to personalized medicine trends and structure of deals entered into by leading companies worldwide.

Personalized Medicine Partnering Terms and Agreements includes:

Trends in personalized medicine dealmaking in the biopharma industry since 2010
Analysis of personalized medicine deal structure
Access to headline, upfront, milestone and royalty data and contract documents
Case studies of real-life personalized medicine deals
Access to over 1000 personalized medicine deal announcements
The leading personalized medicine deals by value since 2010
Most active personalized medicine dealmakers since 2010
The leading personalized medicine partnering resources In Personalized Medicine Partnering Terms and Agreements, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1000 personalized medicine deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise personalized medicine rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture? o How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in personalized medicine dealmaking
2.1. Introduction
2.2. Personalized medicine partnering over the years
2.2.1 Biomarker partnering over the years
2.2.2 Companion diagnostic partnering over the years
2.2.3 Pharmacogenomics partnering over the years
2.3. Big pharma personalized medicine dealmaking activity
2.3.1 Big pharma biomarker, companion diagnostic and pharmacogenomics dealmaking activity
2.4. Most active in personalized medicine
2.5. Personalized medicine partnering by deal type
2.5.1 Biomarker partnering by deal type
2.5.2 Companion diagnostic partnering by deal type
2.5.3 Pharmacogenomics partnering by deal type
2.6. Personalized medicine partnering by disease type
2.6.1 Biomarker partnering by disease type
2.6.2 Companion diagnostic partnering by disease type
2.6.3 Pharmacogenomics partnering by disease type
Chapter 3 – Average financial deal terms for personalized medicine partnering
3.1 Personalized medicine headline values by year
3.2 Personalized medicine upfront payments by year
3.3 Personalized medicine milestone payments by year
3.4 Personalized medicine royalty rates by year
Chapter 4 – Leading biomarker deals
4.1. Introduction
4.2. Top biomarker deals by value
Chapter 5 – Leading companion diagnostic deals
5.1. Introduction
5.2. Top companion diagnostic deals by value
Chapter 6 – Leading pharmacogenomics deals
6.1. Introduction
6.2. Top pharmacogenomics deals by value
Chapter 7 – Big pharma personalized medicine deals
7.1. Introduction
7.2. How to use big pharma personalized medicine partnering deals
7.3. Big pharma personalized medicine partnering company profiles
Chapter 8 – Biomarker contracts dealmaking directory
8.1. Introduction
8.2. Biomarker partnering deals with a contract available by company A-Z
8.3. Biomarker partnering deals with a contract available by by deal type
8.4. Biomarker partnering deals with a contract available by therapy type
Chapter 9 – Companion diagnostic contracts dealmaking directory
9.1. Introduction
9.2. Companion diagnostic partnering deals with a contract available by company A-Z
9.3. Companion diagnostic partnering deals with a contract available by deal type
9.4. Companion diagnostic partnering deals with a contract available by therapy area
Chapter 10 – Pharmacogenomics contracts dealmaking directory
10.1. Introduction
10.2. Pharmacogenomics partnering deals with a contract available by company A-Z
10.3. Pharmacogenomics partnering deals with a contract available by deal type
10.4. Pharmacogenomics partnering deals with a contract available by therapy area
Chapter 11 – Personalized medicine dealmaking directory by specific technology type
Biomarkers
Companion Diagnostics
Pharmacogenomics
Personalized medicine
Chapter 12 – Future trends and companies in personalized medicine deal making
12.1. Introduction
12.2. Emerging companies to watch in 2015
12.3. Emerging companies dealmaking in 2010-2015
12.4. Emerging company financings in 2010-2015
Conclusion
Personalized medicine partnering resource center
Online personalized medicine partnering
Personalized medicine partnering events
Further reading on personalized medicine dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering
Order Form – Upgrades to subscription access products
Order Form – Reports
Appendix
Appendix 1: Personalized medicine deals by company A-Z
Appendix 2: Personalized medicine deals by deal type
Appendix 3: Personalized medicine deals by therapy type
Table of figures
Figure 1: Personalized medicine partnering since 2010
Figure 2: Biomarker partnering since 2010
Figure 3: Companion diagnostics partnering since 2010
Figure 4: Pharmacogenomics partnering since 2010
Figure 5: Big pharma – top 50 – personalized medicine deals 2010 to 2015
Figure 6: Big pharma personalized medicine deal frequency – 2010 to 2015
Figure 7: Big pharma – top 50 – biomarker, companion diagnostic and pharmacogenomics deals 2010 to 2015
Figure 8: Big pharma biomarker deal frequency – 2010 to 2015
Figure 9: Big pharma companion diagnostic deal frequency – 2010 to 2015
Figure 10: Big pharma pharmacogenomics deal frequency – 2010 to 2015
Figure 11: Most active in personalized medicine partnering 2010-2015
Figure 12: Most active in biomarkers partnering 2010-2015
Figure 13: Most active in companion diagnostic partnering 2010-2015
Figure 14: Most active in pharmacogenomics partnering activity 2010-2015
Figure 15: Personalized medicine partnering by deal type since 2010
Figure 16: Biomarker partnering by deal type since 2010
Figure 17: Companion diagnostics partnering by deal type since 2010
Figure 18: Pharmacogenomics partnering by deal type since 2010
Figure 19: Personalized medicine partnering by disease type since 2010
Figure 20: Personalized medicine partnering by oncology target since 2010
Figure 21: Biomarker partnering by disease type since 2010
Figure 22: Biomarker partnering by oncology target since 2010
Figure 23: Companion diagnostics partnering by disease type since 2010
Figure 24: Companion diagnostic partnering by oncology target since 2010
Figure 25: Pharmacogenomics partnering by disease type since 2010
Figure 26: Pharmacogenomics partnering by oncology target since 2010
Figure 27: Personalized medicine deals with a headline value by year- 2015
Figure 28: Personalized medicine deals with a headline value by year- 2014
Figure 29: Personalized medicine deals with a headline value by year- 2013
Figure 30: Personalized medicine deals with a headline value by year- 2012
Figure 31: Personalized medicine deals with a headline value by year- 2011
Figure 32: Personalized medicine deals with a headline value by year- 2010
Figure 33: Personalized medicine deals with an upfront value by year- 2015
Figure 34: Personalized medicine deals with an upfront value by year- 2014
Figure 35: Personalized medicine deals with an upfront value by year- 2013
Figure 36: Personalized medicine deals with an upfront value by year- 2012
Figure 37: Personalized medicine deals with an upfront value by year- 2011
Figure 38: Personalized medicine deals with an upfront value by year- 2010
Figure 39: Personalized medicine deals with a milestone value by year- 2015
Figure 40: Personalized medicine deals with a milestone value by year- 2014
Figure 41: Personalized medicine deals with a milestone value by year- 2013
Figure 42: Personalized medicine deals with a milestone value by year- 2012
Figure 43: Personalized medicine deals with a milestone value by year- 2011
Figure 44: Personalized medicine deals with a milestone value by year- 2010
Figure 45: Personalized medicine deals with a royalty rate value by year- 2015
Figure 46: Personalized medicine deals with a royalty rate value by year- 2014
Figure 47: Personalized medicine deals with a royalty rate value by year- 2013
Figure 48: Personalized medicine deals with a royalty rate value by year- 2012
Figure 49: Personalized medicine deals with a royalty rate value by year- 2011
Figure 50: Personalized medicine deals with a royalty rate value by year- 2010
Figure 52: Top biomarker deals by value since 2010
Figure 53: Top companion diagnostic deals by value since 2010
Figure 54: Top pharmacogenomics deals by value since 2010
Figure 55: Online partnering resources
Figure 56: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *